DEUTSCH WINS TWO NOVARTIS DRUG ACCOUNTS

Value of Accounts Not Known

By Published on .

A correction has been made in this story. See below for details.

NEW YORK (AdAge.com) -- Novartis has tapped Interpublic Group of Cos.' Deutsch, New York, for two direct-to-consumer drug accounts, executives close to the matter said.

The agency has won the Zelnorm account and the assignment for Diovan. The value of the accounts is not known.

Deutsch won the Zelnorm

Related Stories:
NOVARTIS NARROWS REVIEW FOR HYPERTENSION DRUG
Drug Maker Asks If Marketing Efforts for Diovan Should Use DTC Ads
DEUTSCH GETS $25 MILLION NOVARTIS ACCOUNT
Work Is for Lamisil Toenail Fungus Treatment
account over Omnicom Group's Cline, Davis & Mann, New York, the executives said.

Other contenders in the Diovan review were Grey Global Group's Grey Worldwide; Omnicom's Merkley Newman Harty; and Havas' Arnold Worldwide Partners. In the Diovan pitch, each agency partnered with shops that specialize in reaching health-care professionals.

A representative for Novartis did not immediately return a call for comment.

The two new accounts join Novartis' Lamisil assignment already at Deutsch.

Diovan treats hypertension, Zelnorm treats irritable bowel syndrome and Lamisil toenail fungus.

Hillary Chura and Rich Thomaselli contributed to this report.

~ ~ ~

CORRECTION: The original version of this story incorrectly reported that the Zelnorm account was worth $80 million. The value of the account cannot be confirmed.

Most Popular